HENMT1 promotes the proliferation and migration of gastric cancer by activating the PI3K-AKT-mTOR signaling pathway

doi:10.3969/j.issn.1674-8115.2025.06.006

Abstract

Abstract:

Objective ·To investigate the role of HEN methyltransferase 1 (HENMT1) in the proliferation and migration of gastric cancer (GC) and its potential molecular mechanisms. Methods ·The expression of HENMT1 in GC was examined using bioinformatics databases, Western blotting and quantitative real-time PCR (qPCR). Kaplan-Meier Plotter and BEST online tools were used to analyze the correlations between HENMT1 expression and overall survival, perineural invasion, subtypes, tumor location and Lauren classification in clinical GC patients. GC cells were cultured in vitro and treated with small interfering RNA (siRNA) targeting HENMT1 and HENMT1 overexpression vectors, in combination with a PI3K activator (740 Y-P) or PI3K inhibitor (3-MA). The roles of HENMT1 in GC cell proliferation and migration were assessed using cell counting kit-8 (CCK-8) assay, colony formation assay, wound healing assay and Transwell migration assay. Results ·HENMT1 was significantly upregulated in GC and positively associated with perineural invasion. Its expression was closely related to GC subtypes, being most pronounced in the proliferative subtype, and was higher in intestinal-type GC according to the Lauren classification. However, HENMT1 expression showed no significant correlation with overall survival or tumor location (including gastric body, cardia, antrum and whole stomach). Functional experiments demonstrated that silencing HENMT1 inhibited GC cell proliferation and migration, whereas overexpression of HENMT1 enhanced these capabilities. Mechanistically, silencing HENMT1 reduced the levels of phosphorylated PI3K, AKT and mTOR, as well as their total protein expression. Conversely, HENMT1 overexpression upregulated these proteins. Moreover, siHENMT1 combined with the PI3K activator 740 Y-P effectively reversed the proliferation and migration effects induced by 740 Y-P, while overexpressed HENMT1 combined with the PI3K inhibitor 3-MA reversed the suppressive effects of 3-MA on GC cell proliferation and migration. Conclusion ·HENMT1 is highly expressed in GC and positively regulates the proliferation and migration of gastric cancer cells by activating the PI3K-AKT-mTOR signaling pathway.

Key words: HEN methyltransferase 1 (HENMT1), gastric cancer (GC), PI3K-AKT-mTOR signaling pathway, proliferation, migration

CLC Number:

R735.2

YANG Na, LIU Junli, BAI Jing, YANG Siyi, HAN Jiming, ZHANG Huahua. HENMT1 promotes the proliferation and migration of gastric cancer by activating the PI3K-AKT-mTOR signaling pathway[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(6): 717-726.

Figures/Tables 7

Tab 1 Primer sequences for qPCR

Gene	Forward primer (5'→3')	Reverse primer (5'→3')
HENMT1	ATCCATGATTGTCATCAGCACAC	TTGCCACATATAAAGCCCAGG
GAPDH	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG

Tab 2 Sequences of siRNA

siRNA	Sense(5'→3')	antisense(5'→3')
siNC	UUCUCCGAACGUGUCACGUTT	ACGUGACACGUUCGGAGAATT
siHENMT1-1	GGCCAAGAUAGAGAACUCUTT	AGAGUUCUCUAUCUUGGCCTT
siHENMT1-2	CCUCGGGAUCUGAAUUUGATT	UCAAAUUCAGAUCCCGAGGTT

Fig 1 Expression of HENMT1 in GC

Fig 2 Clinical correlation analysis of HENMT1 in GC

Fig 3 Silencing HENMT1 inhibits proliferation and migration of GC cells

Fig 4 HENMT1 promotes proliferation and migration of gastric cancer cells

Fig 5 HENMT1 regulates proliferation and migration of GC cells via PI3K-AKT-mTOR signaling pathway

TrendMD

References 21

[1]	YAN L J, CHEN Y, CHEN F, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up[J]. Gastroenterology, 2022, 163(1): 154-162.e3.
[2]	ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
[3]	XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
[4]	FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[5]	FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 global cancer statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22.
[6]	BILLI A C, ALESSI A F, KHIVANSARA V, et al. The Caenorhabditis elegans HEN1 ortholog, HENN-1, methylates and stabilizes select subclasses of germline small RNAs[J]. PLoS Genet, 2012, 8(4): e1002617.
[7]	HUANG R H. Unique 2'-O-methylation by Hen1 in eukaryotic RNA interference and bacterial RNA repair[J]. Biochemistry, 2012, 51(20): 4087-4095.
[8]	LIM S L, QU Z P, KORTSCHAK R D, et al. HENMT1 and PiRNA stability are required for adult male germ cell transposon repression and to define the spermatogenic program in the mouse[J]. PLoS Genet, 2015, 11(10): e1005620.
[9]	戴馨缘, 王仿竹, 靳佳川, 等. 小RNA 2'-O-甲基转移酶Henmt1在小鼠精子发生中的作用[J]. 南京医科大学学报(自然科学版), 2020,40:1263-1268.
	DAI X Y, WANG F Z, JIN J C, et al. Roles of small RNA 2'-O-methyltransferase Henmt1 during mouse spermatogenesis[J]. Journal of Nanjing Medicial University (Natural Sciences), 2020,40:1263-1268.
[10]	BEGIK O, LUCAS M C, LIU H L, et al. Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures[J]. Genome Biol, 2020, 21(1): 97.
[11]	LEE E, LOKMAN N A, OEHLER M K, et al. A comprehensive molecular and clinical analysis of the PiRNA pathway genes in ovarian cancer[J]. Cancers (Basel), 2020, 13(1): 4.
[12]	HEMPFLING A L, LIM S L, ADELSON D L, et al. Expression patterns of HENMT1 and PIWIL1 in human testis: implications for transposon expression[J]. Reproduction, 2017, 154(4): 363-374.
[13]	REYIMU A, XING F, ZHOU W B, et al. Screening of potential key genes in esophageal cancer based on RBP and expression verification of HENMT1[J]. Medicine (Baltimore), 2023, 102(49): e36544.
[14]	ZHENG Y, MENG X W, YANG J P. Exploring potential regulatory anesthetic drugs based on RNA binding protein and constructing CESC prognosis model: a study based on TCGA database[J]. Front Surg, 2022, 9: 823566.
[15]	FATTAHI S, AMJADI-MOHEB F, TABARIPOUR R, et al. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond[J]. Life Sci, 2020, 262: 118513.
[16]	ZHAO W D, ZHAO X H, XU M L, et al. Knockdown of LINC01279 suppresses gastric cancer proliferation and migration by inhibiting PI3K/Akt/mTOR signaling pathway[J]. J Oncol, 2022, 2022: 6228982.
[17]	GU X J, LI Y J, WANG F, et al. miR-30e-3p inhibits gastric cancer development by negatively regulating THO complex 2 and PI3K/AKT/mTOR signaling[J]. World J Gastrointest Oncol, 2022, 14(11): 2170-2182.
[18]	LI H, ZHAO S F, SHEN L W, et al. E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer[J]. Aging (Albany NY), 2021, 13(10): 13626-13643.
[19]	WANG N, DONG Q, ZHOU X N. LMO4 promotes the invasion and proliferation of gastric cancer by activating PI3K-Akt-mTOR signaling[J]. Am J Transl Res, 2019, 11(10): 6534-6543.
[20]	HU F F, HE Z K, SUN C N, et al. Knockdown of GRHL2 inhibited proliferation and induced apoptosis of colorectal cancer by suppressing the PI3K/Akt pathway[J]. Gene, 2019, 700: 96-104.
[21]	BAGHERY SAGHCHY KHORASANI A, POURBAGHERI-SIGAROODI A, PIRSALEHI A, et al. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions[J]. Eur J Pharmacol, 2021, 898: 173983.